Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

This study has been completed.
Information provided by:
Baxalta US Inc. Identifier:
First received: September 8, 2005
Last updated: June 26, 2015
Last verified: October 2006
The purpose of this study is to assess the safety and efficacy of Immune Globulin Intravenous (Human), 10% (IGIV 10%) in subjects with primary immunodeficiency disorders.

Condition Intervention Phase
Primary Immunodeficiency Disorders
Immune Thrombocytopenic Purpura (ITP)
Kawasaki Syndrome
Biological: Immune Globulin Intravenous (Human), 10%
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Clinical Investigation to Assess the Safety and Efficacy of Immune Globulin Intravenous (Human), 10% in Subjects With Primary Immunodeficiency Disorders

Resource links provided by NLM:

Further study details as provided by Baxalta US Inc.:

Study Start Date: June 2002
Estimated Study Completion Date: December 2003

Ages Eligible for Study:   24 Months and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent obtained from either the subject or the subject's legally acceptable representative prior to any study-related procedures and study product administration
  • Diagnosis of a PID disorder as defined by World Health Organization criteria for which the subject has been receiving a regimen of IGIV infusions every 21 to 28 days over a period of at least 4 months pre-study at a dose of 300-600 mg/kg body weight
  • Subjects > 24 months of age
  • A negative serum pregnancy test for any female subject who is of childbearing potential.

Exclusion Criteria:

  • Subjects sero-positive at enrollment for one or more of the following: hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus (HCV), antibodies to human immunodeficiency virus (HIV) Types 1 or 2
  • Subjects with levels of alanine amino transferase (ALT) and aspartate amino transferase (AST) > 2.5 times the upper limit of normal for the testing laboratory. An AST > 2.5 times the upper limit of normal is allowable, if the ALT does not exceed the upper limit of the reference range for the testing laboratory
  • Subjects with neutropenia (defined as an ANC >= 1,000/mm3)
  • Subjects with serum creatinine levels greater than two times the upper limit of normal for age and gender
  • Subjects with malignancy or a history of malignancy
  • Subjects who received any blood or blood product exposure other than an IGIV and/or immune serum globulin (ISG) preparation within the 6 months prior to study entry
  • Subjects with an ongoing history of hypersensitivity or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IGIV and/or ISG infusions
  • Subjects with selective complete IgA deficiency
  • Subjects with moderate levels of anti-IgA antibodies (>150), or subjects with lower anti-IgA antibodies who are naive to IGIV treatment. (Subjects with lower levels of IgA antibodies, whom the investigators know to have tolerated IgA containing IGIV preparations in the past, may be included if the investigator is comfortable with this)
  • Subjects receiving antibiotic therapy for the treatment of infection within 30 days prior to enrollment
  • Subjects who receive prophylactic antibiotics as part of their care regimen
  • Subjects participating in another clinical study involving an investigational product or device within 30 days prior to study entry
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00157079

United States, California
Children´s Hospital Los Angeles
Los Angeles, California, United States, 90027
Stanford University Medical Center
Stanford, California, United States, 94304-8786
United States, Colorado
1st Allergy and Clinical Research Center
Engelwood, Colorado, United States, 80112
United States, Florida
Allergy Associates of the Palm Beaches
North Palm Beach, Florida, United States, 33408
University of South Florida; Asthma, Allergy & Immunology CRU
Tampa, Florida, United States, 33613
United States, Illinois
Rush Presbyterian - St. Lukes Medical Center
Chicago, Illinois, United States, 60612
United States, Massachusetts
Children´s Hospital Boston
Boston, Massachusetts, United States, 02115
United States, Nebraska
Allergy, Asthma & Immunology Assoc.
Omaha, Nebraska, United States, 68124
Asthma and Allergy Center
Papillion, Nebraska, United States, 68046
United States, New York
Montefiore Medical Center, Albert Einstein College of Medicine
Bronx, New York, United States, 10461
United States, Texas
Pediatric Allergy/Immunology Associates
Dallas, Texas, United States, 75230
Sponsors and Collaborators
Baxalta US Inc.
Principal Investigator: Joseph Church, MD Children´s Hospital Los Angeles, LA, CA
Principal Investigator: Roger Kobayashi, MD Allergy, Asthma & Immunology Assoc., Omaha, NE
Principal Investigator: Dennis Ledford, MD Asthma, Allergy & Immunology CRU, University of South Florida, Tampa, FL
Principal Investigator: Isaac Melamed, MD First Allergy and Clinical Research Center, Engelwood, CO
Principal Investigator: James Moy, MD Rush Presbyterian - St. Lukes Medical Center, Chicago, IL
Principal Investigator: Arye Rubinstein, MD Albert Einstein College of Medicine, Bronx, NY
Principal Investigator: Lynda Schneider, MD Children´s Hospital, Boston, MA
Principal Investigator: Linda Ford, MD Asthma and Allergy Center, Papillion, NE
Principal Investigator: Mark Stein, MD Allergy Associatesof the Palm Beaches, North Palm Beach, FL
Principal Investigator: Richard L. Wasserman, MD Pediatric Allergy/Immunology Associates, Dallas, TX
Principal Investigator: Dale T. Umetsu, MD, PhD Stanford University Medical Center, Stanford, CA
  More Information Identifier: NCT00157079     History of Changes
Other Study ID Numbers: 160101
Study First Received: September 8, 2005
Last Updated: June 26, 2015

Keywords provided by Baxalta US Inc.:
Immune Thrombocytopenic Purpura (ITP)
Kawasaki syndrome

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
Mucocutaneous Lymph Node Syndrome
Pathologic Processes
Immune System Diseases
Blood Coagulation Disorders
Hematologic Diseases
Skin Manifestations
Signs and Symptoms
Thrombotic Microangiopathies
Blood Platelet Disorders
Hemorrhagic Disorders
Autoimmune Diseases
Vascular Diseases
Cardiovascular Diseases
Lymphatic Diseases
Skin Diseases, Vascular
Skin Diseases
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors processed this record on April 28, 2017